Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ®
News announced by Exelixis (EXEL) about encouraging results from the combination of its product cabozantinib (CABOMETYX®) with Roche’s product atezolizumab (TECENTRIQ . . .
This content is for paid subscribers.
Impacting News
February 11, 2020
